GE Healthcare, a provider of medical technologies and services, has received the FDA approval for Cysview, which is used for the detection of non-muscle-invasive papillary cancer of the bladder in patients with known or suspected bladder cancer.
According to the company, Cysview is an optical imaging agent indicated for use in the cystoscopic detection of non-muscle-invasive papillary cancer of the bladder among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy.
Eric Cantor, head of medical affairs for medical diagnostics business in the America of GE Healthcare, said: "Phase III clinical data supplied with the new drug application demonstrated a significantly improved rate of detection of non-muscle-invasive papillary cancer using Cysview cystoscopy compared to standard white light cystoscopy alone in patients with non-muscle-invasive papillary bladder cancer.
"The use of Cysview and blue light cystoscopy enables physicians to detect bladder tumors more accurately than with standard white light technology. The introduction of Cysview is a reflection of our commitment to providing innovative advances in diagnostic oncology."
Source: GE Healthcare
Tuesday, June 1, 2010
Subscribe to:
Post Comments (Atom)
